Jee-Hyun Kong, Ph.D.

Affiliations: 
Neuroscience Johns Hopkins University, Baltimore, MD 
Google:
"Jee-Hyun Kong"
Mean distance: 14.47 (cluster 6)
 
SNBCP

Parents

Sign in to add mentor
Paul A. Fuchs grad student 2009 Johns Hopkins
 (Comparative studies of efferent cholinergic inhibition in cochlear inner and outer hair cell.)
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Kong JH, Winton EF, Heffner LT, et al. (2020) Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors. Journal of Clinical Medicine. 9
Kong JH, Nam H, Go TH, et al. (2019) Characteristics and survival of patients with atypical chronic myeloid leukemia. Blood Research. 54: 233-236
Kim SJ, Yoon DH, Kang HJ, et al. (2019) Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma. Bmc Cancer. 19: 1080
Oh SY, Kim WS, Kim JS, et al. (2019) Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study. Cancer Communications (London, England). 39: 58
Seo HY, Ko TH, Hyun SY, et al. (2019) Tyrosine Kinase Inhibitor Dosing Patterns in Elderly Patients With Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma & Leukemia
Hyun SY, Na EJ, Jang JE, et al. (2019) Induction of apoptosis and differentiation by Na/H exchanger 1 modulation in acute myeloid leukemia cells. Biochemical and Biophysical Research Communications
Sung PH, Im C, Hyun SY, et al. (2017) Unusual isolated extramedullary relapse of acute lymphoblastic leukemia in the breast despite complete donor hematopoietic chimerism after allogeneic hematopoietic stem cell transplantation. The Korean Journal of Internal Medicine
Kwak JY, Kim SH, Oh SJ, et al. (2017) Phase III clinical trial (RERISE study) results of Efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research
Kong JH, Khoury HJ, Kim AS, et al. (2017) The Safety of Bosutinib for the Treatment of Chronic Myeloid Leukemia. Expert Opinion On Drug Safety
Kong JH, Winton EF, Heffner LT, et al. (2017) Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia? Cancer
See more...